CSL investors see limited direct impact from U.S. pricing deals
UBS analysts cited by market talk say CSL’s U.S. pricing agreements—giving Medicaid access at comparable prices—are unlikely to have much direct financial impact.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.